<DOC>
	<DOCNO>NCT00828672</DOCNO>
	<brief_summary>Phase II clinical trial , open-label , randomize , two arm , multicentre ( possibly multinational ) . Academic , investigator initiate . To assess activity bevacizumab ( AvastinTM ) combination capecitabine ( XelodaTM ) radiation therapy without oxaliplatin ( EloxatinTM ) pre-operative treatment locally advanced rectal cancer , follow TME ( total mesorectal excision ) .</brief_summary>
	<brief_title>Phase II Study Neo Adjuvant Treatment With Avastin , Xeloda and/or Eloxatin Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patient least 18 year age Good organ function Locally advance ( accord RECIST criterion ) adenocarcinoma rectum Evidence distant metastasis Contraindication bevacizumab Pregnant breastfeeding woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>ass activity</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>capecitabine</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>pre-operative treatment</keyword>
	<keyword>TME ( total mesorectal excision ) .</keyword>
</DOC>